FDA Guidance for Industry

FDA. Guidance for Industry. PAT—A Framework for Innovative Pharmaceutical Development, Mannfactnring, and Qnality Assurance, http //www.fda.gov/cder/ guidence/6419fnl.htm... 

FDA Guidance for Industry Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/ Active Ingredients Based on a Biopharmaceutics Classification System, CDER-GUID 2062dft.wpd Draft, Jan. 1999. 

FDA, Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. For further informatio, visit http // www.fda.gov/cder/guidance/ index.htm. 

FDA, Guidance for Industry Drugs, Biologies, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals (Draft Guidance). United States Food and Drug Administration,... 

FDA Guidance for Industry, Part 11, Electronic Records Electronic Signatures - Scope and Application (Final version, August 2003), Center for Dmg Evaluation and Research (CDER), US Food and Drug Administration (FDA), Beltsville, MD, USA, 2003. 

FDA. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (Revised) (I). Rockville MD, USA U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2003. 

FDA. Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville Center for Drug Evaluation and Research, 1997. 

FDA, Guidance for industry Dissolution testing of immediate release solid oral dosage forms, 1997. 

FDA, Guidance for Industry Extended Release Oral Dosage Forms Development, Evaluation, and Application of In Vitro/In Vivo Correlation, 1997. 

FDA, Guidance for Industry Single Dose Acute Toxicity Testing for Pharmaceuticals, August... 

Food and Drug Administration (FDA). Guidance for industry, pharmacogenomics data submissions. Available at http //www.fda.gov/cber/gdlns/pharmdtasub.htm. Accessed March 31, 2005. 

FDA, Guidance for industry PAT - A framework for innovative pharmaceutical development, manufacturing and quality assurance, available http //www.fda.gov/cder/guidance/6419fnl.pdf... 

US FDA Guidance for Industry Process validation General Principles and Practice, Draft guidance, November... 

FDA, Guidance for Industry, Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (Mar 2000). This guidance document also discusses the definition of a court to trigger the 180-day exclusivity, see Chapter 5. 

FDA Guidance for Industry. In Vivo Metafco/ism/Dray Interaction Studies - Study Design, Data Analysis and Recommendations for Dosing and Labelling. Rockville, MD FDA, 1999. 

FDA, Guidance for Industry Consumer-Directed Broadcast Advertisements. Washington, DC FDA, Draft July 1997, Final August 1999. 

Food and Drug Administration (FDA) Guidance for Industry-Internet Reference... 

FDA Guidance for Industry Analytical Procedures and Methods Validation (draft),... 

FDA Guidance for Industry, Bioanalytical Method Validation, May 2001 (available from www.fda.gov). 

FDA guidance for industry Part 11 Electronic Records and Electronic Signature Scope and Applications, draft February 2003, final version August 2003. 

FDA Guidance for Industry on the Submission of Documentation for the Sterilization Process Validation in Applications for Human and Veterinary Drug Products (November 1994)... 

FDA Guidance for Industry on the Content and Format on Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well Characterized, Therapeutic, Biotechnology-Derived Products (November 1995)... 

---